Investors cautious over Lipitor patent challenges

Share this article:

Investors are betting cautiously on Pfizer's Lipitor, which could either continue its unprecedented surge or take a huge sales hit, depending on the outcome of ongoing patent litigation.
Deutsche Bank large-cap pharmaceuticals analyst Barbara Ryan told CNN/Money.com yesterday she thinks Pfizer has an 80 percent chance of winning its patent fights, but investors are taking a different view, being very cautious prior to the outcomes of the court battles.
"Investors don't want to make the bet because it's too hard to call," Ryan said.
Pfizer is awaiting verdicts in two court fights with Indian generic drug maker Ranbaxy Laboratories. The Lipitor patent challenges are being decided in a U.S. district court in Delaware as well as a British court. Both companies are awaiting judges' rulings, which could come by the end of the year.
Pfizer holds at least two patents for Lipitor, scheduled to expire in 2010 and 2011.
The cholesterol-lowering treatment was the first drug to break the $10 billion sales mark with 2004 global sales totaling $10.8 billion.
Deutsche Bank projects that Lipitor's global sales will grow to $14.2 billion in 2007 if Pfizer retains the patents. But if Pfizer loses, it could face an $8.6 billion drop in annual sales by 2007.
According to Deutsche Bank analysts, if Ranbaxy succeeds in proving the patents invalid, the company could have a generic version of the drug on the market as early as 2007. Analysts also said Lipitor's competitors, including Crestor and Vytorin, could suffer from declining sales if patients are given the option to switch to cheaper generics.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...